Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT04189445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 5, 2020
Completion date
November 11, 2024
Enrollment
115 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic gastric or gastroesophageal cancer, advanced or metastatic solid tumor, myeloid or lymphoid neoplasms (mln)